Senior executive with 25 years of extensive international experience in the pharmaceutical industry in Rx, Gx and OTC. Last 5 years devoted to Cannabis Industry, mainly in the area of R&D and Regulatory Affairs.
A Ph.D. from Toxicology & Pharmacology, energetic and creative, an all-round business leader who has direct practical knowledge in strategic marketing and operational excellence. Has outstanding business acumen, pragmatic business instinct, excellent communication and negotiation skills with a very solid track record in building customer relationship and staff motivation.
Sciva International Ltd., HQ Prague, Czech Republic 08/2020-Present
Regulatory Affairs Officer & Partner 08/2020-Present
Sciva International is vertically integrated, seeds-to-shelf quality controlled, cannabis company. Established as start up in 2019 with focus on high quality and innovation. The portfolio includes novel foods, cosmetics and bulk. All products are manufactured under EU-GMP conditions, in accordance with valid legislation of the Czech Republic and the European Union. International presence in Europe, Australia, USA.
GRACELAND-International Inc., HQ Toronto, Canada 09/2014-Present
Senior Consultant EMEA, APAC & Partner 09/2014-Present
Graceland-International is a boutique consultancy firm, specialized in Pharmaceutical, Healthcare and Medical Cannabis consulting in all countries over the world. Established in 2014 as start up company. Recent company size is up to 50 employees, HQ in Toronto and Regional Offices in Zürich, Shanghai. Year Turnover over $ 15.3mio.
SANOFI Global Generic Division, HQ Paris, France 02/2011–06/2014
Global Brand Marketing Director 02/2011–06/2014
Sanofi is the 35bn € world´s leading pharmaceutical company providing products in 100 territories. Sanofi Global Gx Division is the 3rd biggest global generic company in the world with annual turnover over 1,5bn €. Offers medicines and services to 1 billion patients. As Global Brand Marketing Director I was responsible for budget of 5mio €, 4 direct and 34 dotted line reports.
TEVA Pharmaceuticals, Utrecht, The Netherlands 08/2003-10/2010
Immunotherapy Business Head Europe 08/2006-10/2010
TEVA is a leading global pharmaceutical company with direct presence in about 60 countries and net revenue $20.3 billion. Generic medicines net revenues represent $9.9 billion. As Immunotherapy Business Head Europe and core member of the European Leadership Team I was responsible for a budget of 15mio € and 18 dotted line reports.
TEVA PHARMACEUTICALS (IVAX Pharmaceuticals) Prague, Czech Republic
Strategic Marketing Director Europe 01/2003 – 07/2006
IVAX Pharmaceuticals, ranked between top 10 Gx pharmaceuticals companies in the world with sales of $2.8bn and direct presence in 70 countries. The company was acquired by TEVA Pharmaceuticals in 2006. As Strategic Marketing Director Europe I was responsible for budget of 2mio € and 12 dotted line reports.
ABBOTT LABORATORIES (Solvay Pharmaceuticals) Prague, Czech Republic 01/1994–12/2002
Business Director 01/2002-12/2002
Solvay Pharmaceutical is Belgian innovative international pharmaceutical company with annual sales of 9,4bn € and direct presence in 50 countries including the U.S.A. The company was acquired by Abbott Laboratories. As Business Director I was responsible for budget of 3mio € and 25 direct sales and marketing reports.
Market Access & Business Development Manager, Atlanta, USA 01/2001-12/2001
1 year assignment.
National Sales & Marketing Manager 01/1994-12/2000
NATIONAL INSTITUTE OF PUBLIC HEALTH (NIPH), Prague 1992-1993
Immunology Specialist responsible for research/development of the new serological methods, completed 3 months project assignments in both Egypt (Cairo) and the USA (Minneapolis).
